Stock Track | SINO BIOPHARM Soars 5.00% Intraday on Completion of Phase III Trial Enrollment for Breast Cancer Drug

Stock Track

Feb 10

SINO BIOPHARM's stock price surged 5.00% during intraday trading on Tuesday, driven by positive clinical development news.

The company announced the completion of patient enrollment for a Phase III clinical trial of its investigational drug TQB2102, a HER2-targeting bispecific antibody-drug conjugate (ADC) for HER2-low recurrent or metastatic breast cancer. This milestone represents significant progress in the drug's development pathway.

Previous Phase Ib clinical results presented at the 2025 American Society of Clinical Oncology annual meeting showed promising efficacy, with an objective response rate of 53.4% in heavily pre-treated patients. The drug's innovative design aims to enhance tumor selectivity and therapeutic effectiveness while managing safety concerns.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1163060577"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163060577\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163060577?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 10:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163060577","market":"sg","top_or_hot":-1,"title":"Stock Track | SINO BIOPHARM Soars 5.00% Intraday on Completion of Phase III Trial Enrollment for Breast Cancer Drug","media":"Stock Track","content":"<p>SINO BIOPHARM's stock price surged 5.00% during intraday trading on Tuesday, driven by positive clinical development news.</p><p>The company announced the completion of patient enrollment for a Phase III clinical trial of its investigational drug TQB2102, a HER2-targeting bispecific antibody-drug conjugate (ADC) for HER2-low recurrent or metastatic breast cancer. This milestone represents significant progress in the drug's development pathway.</p><p>Previous Phase Ib clinical results presented at the 2025 American Society of Clinical Oncology annual meeting showed promising efficacy, with an objective response rate of 53.4% in heavily pre-treated patients. The drug's innovative design aims to enhance tumor selectivity and therapeutic effectiveness while managing safety concerns.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SINO BIOPHARM Soars 5.00% Intraday on Completion of Phase III Trial Enrollment for Breast Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SINO BIOPHARM Soars 5.00% Intraday on Completion of Phase III Trial Enrollment for Breast Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-10 10:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SINO BIOPHARM's stock price surged 5.00% during intraday trading on Tuesday, driven by positive clinical development news.</p><p>The company announced the completion of patient enrollment for a Phase III clinical trial of its investigational drug TQB2102, a HER2-targeting bispecific antibody-drug conjugate (ADC) for HER2-low recurrent or metastatic breast cancer. This milestone represents significant progress in the drug's development pathway.</p><p>Previous Phase Ib clinical results presented at the 2025 American Society of Clinical Oncology annual meeting showed promising efficacy, with an objective response rate of 53.4% in heavily pre-treated patients. The drug's innovative design aims to enhance tumor selectivity and therapeutic effectiveness while managing safety concerns.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1163060577","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163060577","pubTimestamp":1770691244,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SINO BIOPHARM's stock price surged 5.00% during intraday trading on Tuesday, driven by positive clinical development news.The company announced the completion of patient enrollment for a Phase III...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"个股赛道|中国生物制药完成乳腺癌药物III期试验入组盘中大涨5.00%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"SINO BIOPHARM's stock price surged 5.00% during intraday trading on Tuesday, driven by positive clinical development news.The company announced the completion of patient enrollment for a Phase III clinical trial of its investigational drug TQB2102, a HER2-targeting bispecific antibody-drug conjugate (ADC) for HER2-low recurrent or metastatic breast cancer. This milestone represents significant progress in the drug's development pathway.Previous Phase Ib clinical results presented at the 2025 American Society of Clinical Oncology annual meeting showed promising efficacy, with an objective response rate of 53.4% in heavily pre-treated patients. The drug's innovative design aims to enhance tumor selectivity and therapeutic effectiveness while managing safety concerns.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}